We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Genome Editing Application Has Potential in Modifying Human Stem Cells

By LabMedica International staff writers
Posted on 12 Jan 2015
Print article
A unique genome editing tool known as CRISPR has been used by researchers for several years to fit, replace, disrupt, or add to sequences of an organism’s DNA. Now, scientists have shown that the system also precisely and effectively changes human stem cells, which could become a new advance in the use of stem cells for treatment and disease research.

In an online article published November 24, 2014, in the journal Molecular Therapy, the Johns Hopkins University (JHU; Baltimore, MD, USA) scientists reported that the findings could simplify and speed efforts to engineer and customize human-induced pluripotent stem cells (iPSCs) for use as treatments or in the development of model systems to evaluate diseases and test drugs. “Stem cell technology is quickly advancing, and we think that the days when we can use iPSCs for human therapy aren’t that far away,” stated Zhaohui Ye, PhD, an instructor of medicine at the Johns Hopkins University School of Medicine. “This is one of the first studies to detail the use of CRISPR [clustered regularly interspaced short palindromic repeats] in human iPSCs, showcasing its potential in these cells.”

CRISPR was derived from a microbial immune system that contains DNA segments known as clustered regularly interspaced short palindromic repeats. The engineered editing system makes use of an enzyme that nicks together DNA with a snippet of small RNA that guides the tool to where researchers want to introduce cuts or other changes in the genome. Earlier studies have shown that CRISPR can generate genomic alterations or mutations through these interventions far more efficiently than other gene editing techniques, such as TALEN (transcription activator-like effector nuclease).

In spite of CRISPR’s advantages, a recent study suggested that it might also produce a large number of “off-target” effects in human cancer cell lines, specifically modification of genes that researchers did not mean to change. To see if this unwanted effect occurred in other human cell types, Ye; Linzhao Cheng, PhD, a professor of medicine and oncology in the Johns Hopkins University School of Medicine; and their colleagues pitted CRISPR against TALEN in human iPSCs, adult cells reprogrammed to perform similar to embryonic stem cells. Human iPSCs have already demonstrated huge potential for treating and studying disease.

The researchers compared the ability of both genome editing systems to either cut out pieces of known genes in iPSCs or cut out a piece of these genes and replace it with another. As model genes, the researchers used JAK2, a gene that when mutated causes a bone marrow disorder known as polycythemia vera; SERPINA1, a gene that when mutated causes alpha1-antitrypsin deficiency, an inherited disorder that may cause lung and liver disease; and AAVS1, a gene that has been recently found to be a “safe harbor” in the human genome for inserting foreign genes.

Their comparison found that when simply cutting out portions of genes, the CRISPR system was significantly more efficient than TALEN in all three gene systems, inducing up to 100 times more cuts. However, when using these genome editing tools for replacing portions of the genes, such as the disease-causing mutations in JAK2 and SERPINA1 genes, CRISPR and TALEN showed similar effectiveness in patient-derived iPSCs, the researchers reported.

In contrast to the human cancer cell line study’s findings, both CRISPR and TALEN had the same targeting specificity in human iPSCs, targeting only the genes they were designed to affect, according to the investigators. The researchers also found that the CRISPR system has an advantage over TALEN: it can be developed to target only the mutation-containing gene without affecting the healthy gene in patients, where just one copy of a gene is affected.

The findings, together with a related study that was published earlier in Cell Stem Cell, a journal of stem cell research, offer support that CRISPR will be a useful application for editing the genes of human iPSCs with little risk of unwanted effects, according to Drs. Ye and Cheng. “CRISPR-mediated genome editing opens the door to many genetic applications in biologically relevant cells that can lead to better understanding of and potential cures for human diseases,” concluded Dr. Cheng.

Related Links:

Johns Hopkins University


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.